For over 20 years, BIONET Corp. has continuously achieved numerous “industry-firsts.” We were the first to receive approval for cell therapy application in wound care under the "Regulations of Special Medical Techniques." We pioneered the first stem cell storage brand in Taiwan, launched the first umbilical cord mesenchymal stem cell storage service in Asia, and became the first IPO stem cell company in Taiwan. By establishing the world's first “Hybrid Banking Model” to combine the benefits of both private banking and public donation, our database has the largest population of Chinese ethnicity in the cord blood depository listed on BMDW. This database serves both domestic as well as international patients in need.

As a leading biotech company in the stem cell industry, BIONET Corp. is one of the few that possess six cell banks and core technologies, including immune cells, umbilical cord blood stem cells, umbilical cord mesenchymal stem cells, dental pulp stem cells, adult peripheral blood stem cells, and adipose mesenchymal stem cells. Our database and cell units has been searched and utilized by over 38 international medical centers. To date, we have successfully assisted with over 500 transplants for more than 60 different diseases worldwide.

● We’ve received the highest number of case approvals under the“Regulations of Special Medical Techniques”by the Ministry of Health and Welfare in Taiwan. Up to date, 23 cell therapy programs have been approved, which were submitted for various indications including cancer immunotherapy, degenerative join disease/cartilage defects of the knee joints, chronic wound healing, and soft tissue repair. Furthermore, the cure rate for the chronic wounds cases is more than 80 % after tracking for more than one year.

● With more than 20 years of clinical research and experience, five cell therapy products are under development currently, including products for treatment of Acute Respiratory Distress Syndrome (ARDS), Pulmonary Fibrosis, Chronic Renal Failure, Chronic Wounds, and Dry Eye.

● Having multiple achievements and patents for mesenchymal stem cell. Additionally, we provide outsourcing services for CRDMO abroad .